Skip to content
Research Article Open access CC BY 4.0

Hypertension Prevalence in the US Population Varies with Differences in Alpha-1 Antitrypsin Genotype: A Cross Sectional Study

Suchit Kumbhare, Kelly J. Hunt, Paul J. Nietert, Laura Schwarz, Charlie Strange

Journal of Advances in Medicine and Medical Research · pp. 880–888 · Published 10 Oct 2014

10.9734/BJMMR/2015/13447

Abstract

Background: The prevalence of hypertension (HTN) associated with alpha-1 antitrypsin deficiency (AATD) has been studied with indeterminate results. The aim of the study was to prospectively compare the prevalence of HTN before testing in 3 groups of individuals with subsequently normal, moderately deficient, and severely deficient genotypes of AATD with adjustment for differences in demographics and clinical variables. Methods: We performed a cross sectional study using data from the Alpha-1 Coded Testing (ACT) study. The univariate demographic and clinical factors associated with HTN were further analyzed by logistic regression analysis. Results: The prevalence of HTN was 27.2%, 20.6%, and 27.9% for individuals with normal, moderate and severe AATD, respectively (p<0.02). The prevalence of HTN increased with age and an interaction between age, alpha-1 antitrypsin deficiency genotype and HTN was identified. The relative risk of HTN among young moderately deficient individuals was 0.53 (95% CI 0.37-0.76) the risk of young PiMM and PiMS (normal genotype) individuals. There was no significant difference in the risk in older moderately deficient individuals 1.02 (95% CI 0.76-1.37) and individuals with severe AATD 1.10 (95% CI 0.71-1.68) when compared to normal genotypes. Conclusion: Moderate deficiency genotypes (PiMZ, PiSS, PiMNull) have less HTN than normal or severe deficiency genotypes, particularly in young individuals. We speculate that protease inhibitor deficiency over a lifetime allows unopposed proteolysis of vascular connective tissue.Measured comorbidities do not explain these findings. Validation of this data should occur in other AATD cohorts.

Hypertension COPD alpha-1 antitrypsin AATD genotype protease inhibitor.

References (21)

  1. 1 Pathogenesis of Hypertension [DOI]
  2. 2 CaMK4 Gene Deletion Induces Hypertension [DOI]
  3. 3 Epidemiology of cardiovascular disease in the 21st century: Updated updated numbers and updated facts
  4. 4 G-Protein-Coupled Receptor Kinase 2 and Hypertension [DOI]
  5. 5 Prediction of Blood Pressure Changes Over Time and Incidence of Hypertension by a Genetic Risk Score in Swedes [DOI]
  6. 6 Physical and social impact of alpha 1-antitrypsin deficiency: results of a survey [DOI]
  7. 7 Identification of individuals with alpha-1-antitrypsin deficiency by a targeted screening program [DOI]
  8. 8 Cardiovascular and musculskeletal co-morbidities in patients with alpha 1 antitrypsin deficiency [DOI]
  9. 9 Pulmonary emphysema and alpha1-antitrypsin deficiency [DOI]
  10. 10 Protein Misfolding and the Serpinopathies [DOI]
  11. 11 Genetic discoveries in hypertension: steps on the road to therapeutic translation [DOI]
  12. 12 Alpha1‐Antitrypsin Deficiency‐Associated Panniculitis: Case Report and Review of the Literature [DOI]
  13. 13 Genetic testing for Alpha1-antitrypsin deficiency [DOI]
  14. 14 Alpha 1-antitrypsin activity is markedly decreased in Wegener’s granulomatosis [DOI]
  15. 15 Lower numbers of FoxP3 and CCR4 co-expressing cells in an elevated subpopulation of CD4+CD25high regulatory T cells from Wegener's granulomatosis.
  16. 16 Changes in aortic wall stiffness in men with α1-antitrypsin deficiency [DOI]
  17. 17 Does alpha-1-proteinase inhibitor play a protective role in coronary atherosclerosis?
  18. 18 α1‐Antitrypsin deficiency presenting with panniculitis and incidental discovery of chronic obstructive pulmonary disease [DOI]
  19. 19 Alpha-1-antitrypsin and blood pressure [DOI]
  20. 20 α1‐ANTITRYPSIN DEFICIENCY ALLELES AND BLOOD PRESSURE IN AN AUSTRALIAN POPULATION [DOI]
  21. 21 Risk of Ischemic Heart and Ischemic Cerebrovascular Disease Is not Increased in S, Z, and 11478A α 1 -Antitrypsin Carriers of The Copenhagen City Heart Study [DOI]

Cited by 2

Comorbidity Associations with AATD Among Commercially Insured and Medicare Beneficiaries with COPD in the US

R. Sandhaus, C. Strange, G. Stone · International Journal of COPD · 2020

COPD_A_263297 2389..2397

R. Sandhaus, M. Runken, C. Blanchette · 2020

Related research

Article metrics

Real usage data collected on this platform.

57

Page views

0

PDF downloads

27

Outbound clicks

2

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.